The US FDA has approved Prevymis for prophylaxis of CMV disease in adult kidney transplant recipients who are at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-])
The approval was based on the P-III trial of Prevymis vs valganciclovir in a ratio (1:1) in 601 patients which showed that Prevymis was non-inferior to valganciclovir for 1EPs of incidence of CMV disease @52wk. post-kidney transplant, patients with CMV disease (10% vs 12%), efficacy was comparable across all subgroups
AEs leading to treatment discontinuation (4% vs 14%). Prevymis was approved in the US for prophylaxis of CMV inf. & in adults who are CMV-seropositive [R+] & received an allogeneic HSCT; approved in 60+ countries incl. EU member states, Canada, Japan & China
Ref: Globenewswire | Image: Merck
Related News:- Merck and AstraZeneca’s Lynparza (Olaparib) Receive NICE Recommendation for Maintenance Treatment of BRCA-Mutated Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
